Indian government to work on new pharma policy

4 November 2016

The Indian government will soon come up with a new pharma policy to counter the excessive controls thwarting competitiveness and innovation in the sector.

According to a posting by Brand India Pharma, an initiative led by Pharmexcil (Pharmaceutical Export Promotion Council) and IBEF (India Brand Equity Foundation), the policy could include significant and important features including the following:

Disbanding of the National Pharmaceutical Pricing Authority (NPPA) in its current form, delinking price control of essential medicines. Prices could be regulated only in case when required thereby leading to more flexibility.

Licenses of periodic renewal would also be scrapped for manufacturing and sale of drugs and would be given till perpetuity.
The Health Ministry would also work on a process of third party certification and self certification on an annual basis.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK